Evolus Inc (EVL.BE)
| Previous close | 10.90 |
| Open | 11.00 |
| Bid | 10.60 x 0 |
| Ask | 11.20 x 0 |
| Day's range | 10.90 - 11.00 |
| 52-week range | 6.45 - 14.10 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
NEWPORT BEACH, Calif., April 17, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients.
Business WireEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif., April 12, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 9,651 shares of Evolus and an aggregate of 20,971 restricted stock units (RSUs) of the company’s common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of di
Simply Wall St.Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company
Key Insights Given the large stake in the stock by institutions, Evolus' stock price might be vulnerable to their...
